CA
DGX icon

Capitolis Advisors’s Quest Diagnostics DGX Stock Holding History

Capitolis Advisors’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-49,258
Closed -$6.55M – 81
2022
Q2 		$6.55M Hold
49,258
– – 0.34% 51
2022
Q1 		$6.74M Hold
49,258
– – 0.34% 49
2021
Q4 		$8.52M Buy
+49,258
New +$7.49M 0.05% 253
2021
Q3 		– Sell
-4,642
Closed -$613K – 415
2021
Q2 		$613K Sell
4,642
-775
-14% -$101K 0.01% 332
2021
Q1 		$695K Sell
5,417
-2,408
-31% -$297K 0.01% 330
2020
Q4 		$933K Buy
+7,825
New +$954K 0.02% 406

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capitolis Advisors's DGX Position: Q3 2022 in Review

Capitolis Advisors sold out of Quest Diagnostics (DGX) in Q3 2022, closing a stake of 49,258 shares — an estimated $6.55M sold.

Capitolis Advisors first reported a position in DGX in Q4 2020 and held it in 6 quarters. The position peaked at $8.52M in Q4 2021. 808 funds tracked by Wall St. Rank hold DGX as of Q3 2022.

  • Capitolis Advisors reported no remaining Quest Diagnostics position as of Q3 2022 after selling out during the quarter.
  • Capitolis Advisors sold 49,258 Quest Diagnostics shares in Q3 2022, an estimated $6.55M.
  • Capitolis Advisors first reported a position in Quest Diagnostics in Q4 2020 and held it in 6 quarters.
  • Capitolis Advisors's Quest Diagnostics position peaked at $8.52M in Q4 2021.
  • 808 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2022.

Based on Capitolis Advisors's 13F filing for Q3 2022, filed 10 Nov 2022.